You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百奧賽圖(02315.HK)擬開發針對100+靶點全人治療性納米抗體
阿思達克 02-21 11:32
百奧賽圖(02315.HK)宣布啟動「Nano 100計劃」,以開發針對100+靶點的全人治療性納米抗體,包括腫瘤相關抗原、GPCRs、免疫檢查點、細胞因子、神經因子等。 該計劃的目標是依托百奧賽圖自主研發的全人納米抗體小鼠RenNano及高通量體外體內篩選平台,規模化開發全人納米抗體藥物。 百奧賽圖表示,期望通過此計劃與全球生物醫藥及科技公司合作,將其規模化納米抗體開發優勢與合作夥伴在相關治療性藥物,尤其是細胞治療、雙抗、多抗、放射性治療等藥物的開發優勢結合起來,共同開發出具有同類首創或同類最佳潛力的新藥。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account